(NKTR) Community Analysis from
Bulls REASONS TO BUY
Bears REASONS TO SELL
May 19, 2013
(Benzinga,
11/5/10)
Hapoalim Securities raised its price target on Nektar Therapeutics (NASDAQ: NKTR) to $19 from $16. It is reiterating its Buy rating on shares.
In a note to clients, Hapoalim writes, "After the impressive Phase II ovarian and breast...(read more)
(Benzinga,
11/2/10)
Below are the top drug delivery stocks on the NYSE and the NASDAQ in terms of cash.
Hospira Inc (NYSE: HSP) had $1.15 billion in total cash for the latest quarter. HSP's total debt stood at $2.24 billion in the same period.
Elan...(read more)
(Stock Blog Hub,
1/13/10)
Recently, Nektar Therapeutics (NKTR) announced preliminary results from the first stage of phase II study of its experimental ovarian cancer drug, NKTR-102. It has been...(read more)
Nektar Therapeutics (NKTR) Company Overview
There is no analysis for NKTR yet. But you can go to Wikinvest to help create one!
